NAGE

+ Watchlist + Portfolio

Niagen Bioscience, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.17
52-Week Range: $2.87 – $10.52
Market Cap: $249.25M
P/E (TTM): 16.58
EPS (TTM): 0.19
Dividend Yield: —

Advanced Metrics

Price/Book: 3.02
PEG Ratio: —
Return on Equity: 21.80%
Return on Assets: 5.44%
Gross Margin: 64.24%
Operating Margin: 2.35%
Profit Margin: 12.39%
Current Ratio: 6.50
Debt/Equity: 0.03
Total Debt: $2.33M
Free Cash Flow: $1.64M
Revenue Growth: -4.30%
Earnings Growth: -75.00%
Enterprise Value: $185.51M

NAGE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$72.05M	$83.57M	$99.60M	$129.42M
Cost of Revenue	$29.25M	$32.79M	$38.01M	$46.23M
Gross Profit	$42.80M	$50.78M	$61.59M	$83.19M
Research & Development	$4.83M	$4.96M	$6.02M	$6.33M
Selling, General & Admin	$56.60M	$51.42M	$47.84M	$62.56M
Operating Expenses	$61.42M	$56.38M	$53.86M	$68.89M
Operating Income	-$18.63M	-$5.60M	$7.73M	$14.30M
EBITDA	-$16.74M	-$3.89M	$9.21M	$15.75M
Pretax Income	-$16.54M	-$4.94M	$8.86M	$18.19M
Income Tax	—	$0.00	$305.00K	$810.00K
Net Income	-$16.54M	-$4.94M	$8.55M	$17.38M
Diluted EPS	-0.24	-0.07	0.11	0.20
Diluted Shares	69.73M	74.98M	78.13M	85.44M

NAGE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.29M	$27.17M	$44.51M	$64.64M
Receivables	$8.48M	$5.23M	$7.77M	$9.74M
Inventory	$14.68M	$14.53M	$9.19M	$20.42M
Current Assets	$46.57M	$49.53M	$64.10M	$96.81M
Total Assets	$54.06M	$54.96M	$68.28M	$106.41M
Current Liabilities	$17.87M	$20.62M	$17.95M	$19.92M
Total Debt	$4.26M	$3.28M	$2.65M	$2.82M
Total Liabilities	$25.39M	$26.51M	$22.18M	$29.87M
Retained Earnings	-$185.49M	-$190.46M	-$181.91M	-$164.53M
Shareholders' Equity	$28.67M	$28.46M	$46.09M	$76.53M
Working Capital	$28.70M	$28.91M	$46.15M	$76.89M

NAGE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.10M	$7.12M	$12.11M	$13.50M
Capital Expenditure	-$334.00K	-$148.00K	-$163.00K	-$292.00K
Free Cash Flow	-$15.43M	$6.97M	$11.95M	$13.21M
Depreciation & Amortisation	$1.88M	$1.71M	$1.48M	$1.45M
Stock-Based Compensation	$5.74M	$4.75M	$3.66M	$6.07M
Investing Cash Flow	-$334.00K	-$143.00K	-$143.00K	-$292.00K
Financing Cash Flow	$7.65M	-$90.00K	$5.37M	$6.92M
Share Repurchases	—	—	$0.00	-$251.00K
Net Change in Cash	-$7.78M	$6.88M	$17.34M	$20.13M

NAGE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$30.48M	$31.12M	$33.99M	$33.84M	$31.47M
Cost of Revenue	$11.15M	$10.89M	$12.06M	$12.13M	$11.50M
Gross Profit	$19.33M	$20.23M	$21.93M	$21.70M	$19.98M
Research & Development	$1.26M	$1.57M	$1.79M	$1.71M	$1.48M
Selling, General & Admin	$13.30M	$15.47M	$15.90M	$17.89M	$16.92M
Operating Expenses	$14.56M	$17.04M	$17.69M	$19.60M	$18.40M
Operating Income	$4.77M	$3.19M	$4.24M	$2.10M	$1.58M
EBITDA	$5.14M	$3.54M	$4.59M	$2.47M	$2.04M
Pretax Income	$5.23M	$3.74M	$4.80M	$4.42M	$6.74M
Income Tax	$168.00K	$128.00K	$222.00K	$292.00K	$417.00K
Net Income	$5.06M	$3.61M	$4.58M	$4.13M	$6.32M
Diluted EPS	0.06	0.04	0.05	0.05	0.07
Diluted Shares	83.23M	86.24M	86.62M	84.44M	84.57M

NAGE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$55.46M	$60.32M	$64.14M	$64.64M	$66.40M
Receivables	$7.05M	$9.66M	$8.51M	$9.74M	$13.07M
Inventory	$11.19M	$14.41M	$18.79M	$20.42M	$24.02M
Current Assets	$76.22M	$86.68M	$93.62M	$96.81M	$105.12M
Total Assets	$81.34M	$91.53M	$98.14M	$106.41M	$114.33M
Current Liabilities	$20.84M	$22.33M	$22.71M	$19.92M	$22.82M
Total Debt	$3.52M	$3.29M	$3.06M	$2.82M	$2.58M
Total Liabilities	$25.99M	$27.33M	$27.46M	$29.87M	$32.00M
Retained Earnings	-$176.85M	-$173.24M	-$168.66M	-$164.53M	-$158.21M
Shareholders' Equity	$55.34M	$64.19M	$70.68M	$76.53M	$82.33M
Working Capital	$55.38M	$64.35M	$70.90M	$76.89M	$82.30M

NAGE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$7.88M	$1.25M	$3.69M	$679.00K	-$1.19M
Capital Expenditure	-$32.00K	-$135.00K	-$24.00K	-$101.00K	-$61.00K
Free Cash Flow	$7.85M	$1.11M	$3.67M	$578.00K	-$1.25M
Depreciation & Amortisation	$368.00K	$355.00K	$359.00K	$368.00K	$464.00K
Stock-Based Compensation	$1.07M	$1.49M	$1.76M	$1.75M	$1.72M
Investing Cash Flow	-$32.00K	-$135.00K	-$24.00K	-$101.00K	$5.25M
Financing Cash Flow	$3.10M	$3.74M	$148.00K	-$80.00K	-$2.29M
Share Repurchases	$0.00	—	—	—	-$2.35M
Net Change in Cash	$10.96M	$4.86M	$3.82M	$498.00K	$1.76M

Market Snapshot

About

Niagen Bioscience, Inc. is a biotechnology company focused on NAD+ precursor supplements and longevity research. The company develops and markets nicotinamide riboside-based products targeting cellular health and aging.